Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma

被引:111
作者
Friedberg, Joseph S.
Culligan, Melissa J.
Mick, Rosemarie
Stevenson, James
Hahn, Stephen M.
Sterman, Daniel
Punekar, Salman
Glatstein, Eli
Cengel, Keith
机构
[1] Univ Penn, Div Thorac Surg, Dept Radiat Oncol, Dept Biostat & Epidemiol,Div Pulm & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA
关键词
EPP; extrapleural pneumonectomy; macroscopic complete resection; malignant pleural mesothelioma; MCR; MPM; PDT; PFS; photodynamic therapy; progression-free survival; radical pleurectomy; RP;
D O I
10.1016/j.athoracsur.2012.02.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Radical pleurectomy (RP) for mesothelioma is often considered either technically unfeasible or an operation limited to patients who would not tolerate a pneumonectomy. The purpose of this study was to review our experience using RP and intraoperative photodynamic therapy (PDT) for mesothelioma. Methods. Thirty-eight patients (42-81 years) underwent RP-PDT. Thirty five of 38 (92%) patients also received systemic therapy. Standard statistical techniques were used for analysis. Results. Thirty seven of 38 (97%) patients had stage III/IV cancer (according to the American Joint Committee on Cancer [AJCC manual 7th Edition, 2010]) and 7/38 (18%) patients had nonepithelial subtypes. Macroscopic complete resection was achieved in 37/38 (97%) patients. There was 1 postoperative mortality (stroke). At a median follow-up of 34.4 months, the median survival was 31.7 months for all 38 patients, 41.2 months for the 31/38 (82%) patients with epithelial subtypes, and 6.8 months for the 7/38 (18%) patients with nonepithelial subtypes. Median progression-free survival (PFS) was 9.6, 15.1, and 4.8 months, respectively. The median survival and PFS for the 20/31 (64%) patients with N2 epithelial disease were 31.7 and 15.1 months, respectively. Conclusions. It was possible to achieve a macroscopic complete resection using lung-sparing surgery in 97% of these patients with stage III/IV disease. The survival we observed with this approach was unusually long for the patients with the epithelial subtype but, interestingly, the PFS was not. The reason for this prolonged survival despite recurrence is not clear but is potentially related to preservation of the lung or some PDT-induced effect, or both. We conclude that the results of this lung-sparing approach are safe, encouraging, and warrant further investigation. (Ann Thorac Surg 2012;93:1658-67) (C) 2012 by The Society of Thoracic Surgeons
引用
收藏
页码:1658 / 1667
页数:10
相关论文
共 6 条
[1]   Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy [J].
Boeluekbas, Servet ;
Manegold, Christian ;
Eberlein, Michael ;
Bergmann, Thomas ;
Fisseler-Eckhoff, Annette ;
Schirren, Joachim .
LUNG CANCER, 2011, 71 (01) :75-81
[2]   Photodynamic therapy and anti-tumour immunity [J].
Castano, Ana P. ;
Mroz, Pawel ;
Hamblin, Michael R. .
NATURE REVIEWS CANCER, 2006, 6 (07) :535-545
[3]   Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients [J].
Flores, Raja M. ;
Pass, Harvey I. ;
Seshan, Venkatraman E. ;
Dycoco, Joseph ;
Zakowski, Maureen ;
Carbone, Michele ;
Bains, Manjit S. ;
Rusch, Valerie W. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (03) :620-+
[4]   Photodynamic Therapy and the Evolution of a Lung-Sparing Surgical Treatment for Mesothelioma [J].
Friedberg, Joseph S. ;
Mick, Rosemarie ;
Culligan, Melissa ;
Stevenson, James ;
Fernandes, Annemarie ;
Smith, Deborah ;
Glatstein, Eli ;
Hahn, Stephen M. ;
Cengel, Keith .
ANNALS OF THORACIC SURGERY, 2011, 91 (06) :1738-1746
[5]   Photodynamic Therapy as an Innovative Treatment for Malignant Pleural Mesothelioma [J].
Friedberg, Joseph S. .
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2009, 21 (02) :177-187
[6]  
Sugarbaker David J, 2010, Expert Rev Respir Med, V4, P363, DOI 10.1586/ers.10.35